Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast

Journal of Clinical Endocrinology and Metabolism

Volumn 84, Issue 12, 1999, Pages 4559-4565

  Hofseth, Lorne J ^a   Raafat, Ahmed M ^a   Osuch, Janet R ^b   Pathak, Dorothy R ^b   Slomski, Carol A ^b   Haslam, Sandra Z ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; CYCLINE; ESTRADIOL; ESTROGEN; KI 67 ANTIGEN; MEDROXYPROGESTERONE ACETATE; MONOCLONAL ANTIBODY KI 67; PROTEIN ANTIBODY;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; BREAST EPITHELIUM; CANCER RISK; CELL PROLIFERATION; DRUG MIXTURE; FEMALE; HORMONE SUBSTITUTION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL;

EID: 0033305673     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.84.12.4559     Document Type: Article

References (41)

1. Postmenopausal estrogens protect against fractures of the hip and distal radius. A case-control study
2. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogens
3. Menopausal estrogen therapy and protection from death from ischemic heart disease
4. A prospective study of postmenopausal estrogen therapy and coronary heart disease
5. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease
6. Menopausal hormone replacement therapy and breast cancer: A meta-analysis
7. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer from 54 epidemiological studies
8. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women
9. The risk of breast cancer after estrogen and estrogen-progestogen replacement
10. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy
11. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: Results of a prospective study
12. Protection against endometrial carcinoma by combination product oral contraceptives
13. Use of the progestogen challenge test to reduce the risk of endometrial cancer
14. Proliferation of breast epithelial cells in healthy women during the menstrual cycle
15. Proliferation of the breast epithelium in relation to menstrual cycle phase, hormonal use, and reproductive factors
16. Cell proliferation in normal human breast ducts, fibroadenomas, and other ductal hyperplasias measured by nuclear labeling with tritiated thymidine. Effects of menstrual phase, age, and oral contraceptive hormones
17. Oral contraceptive use influences resting breast proliferation
18. Oral contraceptive (OCP) use increases proliferation and decreases oestrogen receptor content of epithelial cells in the normal human breast
19. The effect of age and menstrual cycle upon proliferative activity of the normal human breast
20. Cyclic variation of DNA synthesis in human breast epithelium
21. Proliferative and secretory activity in human breast during natural and artificial menstrual cycles
22. Epithehal proliferation in the normal human breast in relation to endogenous hormones and oral contraceptive use
23. Progesterone effects on deoxyribonucleic acid synthesis in normal mouse mammary glands
24. Progesterone action in normal mouse mammary gland
25. Effects of hormone replacement therapy on the mammary gland of surgically post-menopausal cynomolgus macaques
26. Effects of conjugated estrogens, medroxyprogesterone acetate, and tamoxifen on the mammary glands of macaques
27. The proliferation of normal human breast tissue implanted into athymic nude mice is stimulated by estrogen but not progesterone
28. The effect of estrogen, progesterone, thyroxine and human placental lactogen on DNA synthesis of human breast ductal epithelium maintained in athymic nude mice
29. Experiments on proliferation of normal human breast tissue in nude mice do not show that progesterone does not stimulate breast cells
30. Determination of growth fraction in advanced prostate cancer by Ki-67 immunostaining and its relationship to the time to tumor progression after hormonal therapy
31. Update on proliferation-associated antibodies applicable to formalin-fixed paraffin-embedded tissue and their clinical applications
32. The molecular biology of RU486. Is there a role for anti-progestins in the treatment of breast cancer?
33. Progesterone receptors in human breast cancer. Stoichiometric translocation and nuclear receptor processing
34. Estrogen and progesterone receptors in normal mammary gland during different functional states
35. Existence of two populations of cyclinproliferaing cell nuclear antigen during the cell cycle. Association with DNA replication sites
36. Proliferating cell nuclear antigen is required for DNA excision repair
37. Epithelial proliferation and hormone receptor status in the normal postmenopausal breast and the effects of hormone replacement therapy
38. Increased cell division as a cause of human cancer
39. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk
40. Estradiol and progesterone regulate the proliferation of human breast epithelial cells